Published in Clin Cancer Res on August 05, 2010
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol (2013) 2.19
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol (2012) 1.45
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol (2013) 1.14
WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3. Br J Pharmacol (2014) 1.07
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev (2014) 1.03
Immune markers associated with host susceptibility to infection with West Nile virus. Viral Immunol (2014) 0.98
Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features. Stem Cells Int (2015) 0.91
Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells. DNA Cell Biol (2013) 0.89
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Integr Biol (Camb) (2012) 0.84
Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem (2015) 0.83
NKG2D receptor regulates human effector T-cell cytokine production. Blood (2011) 0.82
SATB1 and 2 in colorectal cancer. Carcinogenesis (2014) 0.82
CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin. Exp Cell Res (2013) 0.80
The Distribution of Human Stem Cell-like Memory T Cell in Lung Cancer. J Immunother (2016) 0.79
SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer. Oncotarget (2016) 0.78
Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis. J Exp Med (2017) 0.77
Analysis of Axin2 expression and function in murine models for pancreatic cancer. Cell Biosci (2016) 0.75
β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight (2017) 0.75
Effects of exercise training on circulating levels of Dickkpof-1 and secreted frizzled-related protein-1 in breast cancer survivors: A pilot single-blind randomized controlled trial. PLoS One (2017) 0.75
The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunology (2015) 0.75
Implication of chemo-resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy. Cancer Sci (2017) 0.75
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol (2003) 15.51
beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 12.97
The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 12.68
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Towards an integrated view of Wnt signaling in development. Development (2009) 6.07
Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science (2010) 6.06
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov (2006) 5.29
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature (1998) 5.16
Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science (2007) 5.08
A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity (2009) 4.42
Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10
Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity (2010) 4.06
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev (2002) 3.80
An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature (1995) 3.78
Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol (2009) 3.67
Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 3.62
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol (2008) 3.46
Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (2001) 2.95
Crystal structure of a beta-catenin/Tcf complex. Cell (2000) 2.93
Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol (2004) 2.90
Diversity of LEF/TCF action in development and disease. Oncogene (2006) 2.84
Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood (2007) 2.78
Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res (2010) 2.67
Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev (2000) 2.65
XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development. Development (1999) 2.56
Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med (2008) 2.52
WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol (2005) 2.50
Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature (2003) 2.42
Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell (2006) 2.40
Critical involvement of Tcf-1 in expansion of thymocytes. J Immunol (1998) 2.28
The beta-catenin--TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival. Nat Immunol (2001) 2.27
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc Natl Acad Sci U S A (2010) 2.05
T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat Immunol (2009) 1.99
Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol (2000) 1.94
The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep (2002) 1.93
Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J (2002) 1.91
Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol (2010) 1.64
Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur J Immunol (2001) 1.63
Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell (2006) 1.63
Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets. Semin Immunol (2009) 1.59
Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J Immunol (2009) 1.54
Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J Immunol (2010) 1.48
APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. Nature (2010) 1.35
Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med (2009) 1.34
The human TCF-1 gene encodes a nuclear DNA-binding protein uniquely expressed in normal and neoplastic T-lineage lymphocytes. Blood (1995) 1.29
Beta-catenin does not regulate memory T cell phenotype. Nat Med (2010) 1.13
AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochem Biophys Res Commun (2010) 1.06
TCF1 and beta-catenin regulate T cell development and function. Immunol Res (2010) 1.06
Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol (2005) 1.01
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood (2003) 0.98
ICAT expression disrupts beta-catenin-TCF interactions and impairs survival of thymocytes and activated mature T cells. Int Immunol (2008) 0.95
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 2.10
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood (2009) 2.02
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res (2011) 2.00
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol (2009) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother (2005) 1.78
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol (2005) 1.74
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 1.67
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc (2012) 1.63
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med (2012) 1.61
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Genetic and phenotypic analysis of alleles of the Drosophila chromosomal JIL-1 kinase reveals a functional requirement at multiple developmental stages. Genetics (2003) 1.48
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res (2003) 1.46
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2010) 1.45
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol (2006) 1.43
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 1.36
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34